CIK 0001826667 · Non-accelerated filer<br>Smaller reporting company
TriSalus Life Sciences, Inc.
Sign in to watch- Ticker
- TLSI
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 853009869
- Phone
- 415 336 8917
- Business address
- 6272 WEST 91ST AVENUE, WESTMINSTER, CO, 80031
- Former names
- MedTech Acquisition Corp, MedTech Acquisition Corporation
Securities
- TLSI Common Stock Nasdaq
- TLSIW Warrant Nasdaq
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,113
- in 3 filings
Net −$4,113. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 26 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-24 | Cox Bryan F. Chief of Research | Grant or award | +40,000 | 166,599 | ||
| 2025-11-24 | Cox Bryan F. Chief of Research | Grant or award · Employee Stock Option (right to buy) | +80,000 | 261,954 | ||
| 2025-11-24 | Patience David Chief Financial Officer | Grant or award | +65,000 | 265,000 | ||
| 2025-11-24 | Patience David Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +130,000 | 668,899 | ||
| 2025-11-24 | Szela Mary T CEO and President | Grant or award | +125,000 | 442,802 | ||
| 2025-11-24 | Szela Mary T CEO and President | Grant or award | +300,000 | 742,802 | ||
| 2025-11-24 | Szela Mary T CEO and President | Grant or award · Employee Stock Option (right to buy) | +250,000 | 1,578,182 | ||
| 2025-08-28 | Patience David Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +248,899 | 538,899 | ||
| 2025-08-14 | Patience David Chief Financial Officer | Grant or award | +200,000 | 200,000 | ||
| 2025-08-14 | Patience David Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +290,000 | 290,000 | ||
| 2025-07-31 | Frankenius Equity AB 10% owner | Conversion | +759,000 | 6,989,748 | ||
| 2025-07-31 | Frankenius Equity AB 10% owner | Conversion · Series A Convertible Preferred Stock | −230,000 | 0 | ||
| 2025-07-31 | MATLIN DAVID J Director | Conversion | +330,000 | 1,271,944 | ||
| 2025-07-31 | MATLIN DAVID J Director | Conversion · Series A Preferred Stock | −100,000 | 0 | ||
| 2025-06-12 | Desai Arjun JJ Director | Grant or award · Director Stock Option (right to buy) | +15,000 | 65,000 | ||
| 2025-06-12 | Gordon Gary B. Director | Grant or award · Director Stock Option (right to buy) | +15,000 | 56,250 | ||
| 2025-06-12 | HICKS KERRY R Director | Grant or award · Director Stock Option (right to buy) | +15,000 | 89,222 | ||
| 2025-06-12 | MATLIN DAVID J Director | Grant or award · Director Stock Option (right to buy) | +15,000 | 65,000 | ||
| 2025-06-12 | Murphy Sean Director | Grant or award · Director Stock Option (right to buy) | +15,000 | 554,681 | ||
| 2025-06-12 | Valle William Director | Grant or award · Director Stock Option (right to buy) | +15,000 | 56,250 |
Page 4 of 9 · 161 trades